What is William Blair’s Forecast for Nevro FY2024 Earnings?

Nevro Corp. (NYSE:NVRO) – Analysts at William Blair raised their FY2024 earnings estimates for shares of Nevro in a research report issued to clients and investors on Tuesday, November 12th. William Blair analyst B. Vazquez now forecasts that the medical equipment provider will post earnings of ($2.59) per share for the year, up from their previous estimate of ($2.90). The consensus estimate for Nevro’s current full-year earnings is ($2.46) per share. William Blair also issued estimates for Nevro’s Q4 2024 earnings at ($0.95) EPS, Q1 2025 earnings at ($0.97) EPS, Q2 2025 earnings at ($0.85) EPS, Q3 2025 earnings at ($0.58) EPS, Q4 2025 earnings at ($0.55) EPS, FY2025 earnings at ($2.85) EPS, Q1 2026 earnings at ($0.78) EPS, Q2 2026 earnings at ($0.59) EPS and Q3 2026 earnings at ($0.63) EPS.

Nevro (NYSE:NVRO) last issued its quarterly earnings data on Monday, November 11th. The medical equipment provider reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.40. Nevro had a negative net margin of 16.54% and a negative return on equity of 23.52%. The firm had revenue of $96.60 million for the quarter, compared to analysts’ expectations of $93.09 million. During the same period in the prior year, the firm earned ($0.65) earnings per share. The company’s quarterly revenue was down 7.0% compared to the same quarter last year.

NVRO has been the topic of several other research reports. Wolfe Research upgraded Nevro from an “underperform” rating to a “peer perform” rating in a report on Thursday, August 8th. Canaccord Genuity Group dropped their target price on shares of Nevro from $8.00 to $7.00 and set a “hold” rating for the company in a research note on Tuesday. JMP Securities reissued a “market perform” rating on shares of Nevro in a research note on Tuesday. Citigroup dropped their price objective on shares of Nevro from $6.89 to $6.00 and set a “neutral” rating for the company in a research report on Tuesday, October 1st. Finally, Wells Fargo & Company cut Nevro from an “equal weight” rating to an “underweight” rating and decreased their price target for the company from $13.00 to $5.50 in a report on Wednesday, August 7th. Three investment analysts have rated the stock with a sell rating and twelve have assigned a hold rating to the company. Based on data from MarketBeat, Nevro currently has a consensus rating of “Hold” and an average price target of $9.10.

Nevro Stock Up 11.1 %

NYSE NVRO opened at $4.52 on Thursday. The stock’s 50 day simple moving average is $5.18 and its 200 day simple moving average is $7.39. Nevro has a one year low of $3.95 and a one year high of $22.64. The firm has a market cap of $169.36 million, a PE ratio of -2.39 and a beta of 0.93. The company has a debt-to-equity ratio of 0.67, a current ratio of 5.02 and a quick ratio of 3.53.

Hedge Funds Weigh In On Nevro

Institutional investors have recently modified their holdings of the business. Nisa Investment Advisors LLC raised its position in Nevro by 1,788.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 6,932 shares of the medical equipment provider’s stock valued at $58,000 after buying an additional 6,565 shares during the last quarter. Intech Investment Management LLC acquired a new stake in shares of Nevro during the 3rd quarter worth about $69,000. SG Americas Securities LLC bought a new stake in shares of Nevro during the third quarter worth approximately $71,000. Quantbot Technologies LP grew its holdings in Nevro by 1,290.4% in the 3rd quarter. Quantbot Technologies LP now owns 14,418 shares of the medical equipment provider’s stock valued at $81,000 after buying an additional 13,381 shares in the last quarter. Finally, Canada Pension Plan Investment Board grew its stake in shares of Nevro by 345.8% in the second quarter. Canada Pension Plan Investment Board now owns 10,700 shares of the medical equipment provider’s stock valued at $90,000 after acquiring an additional 8,300 shares in the last quarter. Institutional investors own 95.52% of the company’s stock.

Nevro Company Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.